The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorMedical University of Warsaw
About this trial
Since the reasons for differential immune reconstitution in HIV-infected patients are still not fully understood, we considered it reasonable to investigate whether the presence of primary HIV drug resistance mutations could be one of the factors of inadequate immune reconstitution.
Evaluation of unfavorable factors of immune reconstitution can help identify patients at risk of persistently low CD4 cell counts and CD4:CD8 ratios and requiring careful monitoring for progression to AIDS.
Eligibility criteria
Qualifiers
HIV-1 confirmed infection
ART naive patients > 18 years
virological suppression after 6 months of ART
available results of HIV genotyping before the start of ART
Disqualifiers
hematologic neoplasms
use of chemotherapy, immunosuppressive drugs and other myelotoxic agents
lack of patient's consent to participate in the study
Trial design
Treatments tested in this trial
- differences in CD4 reconstruction
Treatment groups
50 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov